Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis
Multiple sclerosis (MS) is considered to be a central nervous system (CNS) chronic inflammatory demyelinating disease, affecting more than 2 million individuals worldwide. In this meta-analysis, we aimed to assess the safety and efficacy of autologous mesenchymal stem cells (aMSCs) in treating MS pa...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2019-01-01
|
| Series: | Stem Cells International |
| Online Access: | http://dx.doi.org/10.1155/2019/8536785 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850217370671382528 |
|---|---|
| author | Yang Zhou Xin Zhang Hang Xue Lingling Liu Jie Zhu Tao Jin |
| author_facet | Yang Zhou Xin Zhang Hang Xue Lingling Liu Jie Zhu Tao Jin |
| author_sort | Yang Zhou |
| collection | DOAJ |
| description | Multiple sclerosis (MS) is considered to be a central nervous system (CNS) chronic inflammatory demyelinating disease, affecting more than 2 million individuals worldwide. In this meta-analysis, we aimed to assess the safety and efficacy of autologous mesenchymal stem cells (aMSCs) in treating MS patients. The PubMed, Embase, Cochrane, Web of Science, and Clinical Trial databases were searched in September 2019. The analysis was conducted for three endpoints: transplant-related mortality (TRM), rate of disease progression, and no evidence of disease activity (NEDA) status. RevMan and the metaprop command of the meta package in R was used in assessing the efficacy and safety of aMSCs. Subgroup analyses were performed for exploration of heterogeneity regarding outcomes. Nine studies comprising 133 patients were included in the meta-analysis. The pooled estimate of TRM was 0% (95% confidence interval (CI) 0%–0.3%). The rate of progression was 16% at 6 months (95% CI 10%–27%) and 35% at 1 year (95% CI 27%–46%). Lower 6-month and 1-year progression rates were significantly associated with intrathecal injection (p=0.02; p=0.003). The pooled proportion of NEDA patients at 6 months was 72% (95% CI 58%–89%) and at 1 year was 62% (95% CI 42%–81%). Cell transplantation with aMSCs in MS patients is safe, with the largest benefit profile obtained in patients with aMSCs intrathecal injection. |
| format | Article |
| id | doaj-art-3b3bba7ef06047bc9b19ea123538acb8 |
| institution | OA Journals |
| issn | 1687-966X 1687-9678 |
| language | English |
| publishDate | 2019-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Stem Cells International |
| spelling | doaj-art-3b3bba7ef06047bc9b19ea123538acb82025-08-20T02:08:03ZengWileyStem Cells International1687-966X1687-96782019-01-01201910.1155/2019/85367858536785Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-AnalysisYang Zhou0Xin Zhang1Hang Xue2Lingling Liu3Jie Zhu4Tao Jin5Department of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Neurotraumatic Surgery, The First Hospital of Jilin University, Changchun, ChinaDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaDepartment of Neurology and Neuroscience Center, The First Hospital of Jilin University, Changchun, ChinaMultiple sclerosis (MS) is considered to be a central nervous system (CNS) chronic inflammatory demyelinating disease, affecting more than 2 million individuals worldwide. In this meta-analysis, we aimed to assess the safety and efficacy of autologous mesenchymal stem cells (aMSCs) in treating MS patients. The PubMed, Embase, Cochrane, Web of Science, and Clinical Trial databases were searched in September 2019. The analysis was conducted for three endpoints: transplant-related mortality (TRM), rate of disease progression, and no evidence of disease activity (NEDA) status. RevMan and the metaprop command of the meta package in R was used in assessing the efficacy and safety of aMSCs. Subgroup analyses were performed for exploration of heterogeneity regarding outcomes. Nine studies comprising 133 patients were included in the meta-analysis. The pooled estimate of TRM was 0% (95% confidence interval (CI) 0%–0.3%). The rate of progression was 16% at 6 months (95% CI 10%–27%) and 35% at 1 year (95% CI 27%–46%). Lower 6-month and 1-year progression rates were significantly associated with intrathecal injection (p=0.02; p=0.003). The pooled proportion of NEDA patients at 6 months was 72% (95% CI 58%–89%) and at 1 year was 62% (95% CI 42%–81%). Cell transplantation with aMSCs in MS patients is safe, with the largest benefit profile obtained in patients with aMSCs intrathecal injection.http://dx.doi.org/10.1155/2019/8536785 |
| spellingShingle | Yang Zhou Xin Zhang Hang Xue Lingling Liu Jie Zhu Tao Jin Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis Stem Cells International |
| title | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis |
| title_full | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis |
| title_fullStr | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis |
| title_full_unstemmed | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis |
| title_short | Autologous Mesenchymal Stem Cell Transplantation in Multiple Sclerosis: A Meta-Analysis |
| title_sort | autologous mesenchymal stem cell transplantation in multiple sclerosis a meta analysis |
| url | http://dx.doi.org/10.1155/2019/8536785 |
| work_keys_str_mv | AT yangzhou autologousmesenchymalstemcelltransplantationinmultiplesclerosisametaanalysis AT xinzhang autologousmesenchymalstemcelltransplantationinmultiplesclerosisametaanalysis AT hangxue autologousmesenchymalstemcelltransplantationinmultiplesclerosisametaanalysis AT linglingliu autologousmesenchymalstemcelltransplantationinmultiplesclerosisametaanalysis AT jiezhu autologousmesenchymalstemcelltransplantationinmultiplesclerosisametaanalysis AT taojin autologousmesenchymalstemcelltransplantationinmultiplesclerosisametaanalysis |